Laboratory Corporation of America (LH) Stock Forecast, Price Target & Predictions
LH Stock Forecast
Laboratory Corporation of America stock forecast is as follows: an average price target of $281.25 (represents a 18.08% upside from LH’s last price of $238.18) and a rating consensus of 'Buy', based on 10 wall street analysts offering a 1-year stock forecast.
LH Price Target
The average price target for Laboratory Corporation of America (LH) is $281.25 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $350.00 to $240.00. This represents a potential 18.08% upside from LH's last price of $238.18.
LH Analyst Ratings
According to 10 Wall Street analysts, Laboratory Corporation of America's rating consensus is 'Buy'. The analyst rating breakdown for LH stock is 0 'Strong Buy' (0.00%), 6 'Buy' (60.00%), 4 'Hold' (40.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Laboratory Corporation of America Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 24, 2024 | Elizabeth Anderson | Evercore ISI | $240.00 | $224.72 | 6.80% | 0.76% |
| Sep 23, 2024 | Brian Tanquilut | Jefferies | $265.00 | $222.22 | 19.25% | 11.26% |
| Aug 05, 2024 | Michael Ryskin | Bank of America Securities | $260.00 | $236.00 | 10.17% | 9.16% |
| Aug 02, 2024 | Stephanie Davis | Barclays | $249.00 | $235.67 | 5.66% | 4.54% |
| Aug 02, 2024 | Eric Coldwell | Robert W. Baird | $277.00 | $235.67 | 17.54% | 16.30% |
| Mar 25, 2024 | David Toung | Argus Research | $250.00 | $212.50 | 17.65% | 4.96% |
| Jan 06, 2023 | - | Morgan Stanley | $303.00 | $241.42 | 25.51% | 27.21% |
| Nov 23, 2022 | - | Credit Suisse | $305.00 | $238.00 | 28.15% | 28.05% |
| Jul 29, 2022 | - | Mizuho Securities | $296.00 | $254.72 | 16.21% | 24.28% |
| May 03, 2022 | - | Deutsche Bank | $265.00 | $245.45 | 7.96% | 11.26% |
The latest Laboratory Corporation of America stock forecast, released on Sep 24, 2024 by Elizabeth Anderson from Evercore ISI, set a price target of $240.00, which represents a 6.80% increase from the stock price at the time of the forecast ($224.72), and a 0.76% increase from LH last price ($238.18).
Laboratory Corporation of America Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 6 |
| Avg Price Target | - | $252.50 | $256.83 |
| Last Closing Price | $238.18 | $238.18 | $238.18 |
| Upside/Downside | -100.00% | 6.01% | 7.83% |
In the current month, the average price target of Laboratory Corporation of America stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Laboratory Corporation of America's last price of $238.18. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 30, 2024 | HSBC | - | Buy | Upgrade |
| Oct 01, 2024 | Piper Sandler | - | Neutral | Initialise |
| Sep 23, 2024 | Jefferies | Buy | Buy | Hold |
| Aug 05, 2024 | Bank of America Securities | Buy | Buy | Hold |
| Aug 02, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Aug 02, 2024 | UBS | Buy | Buy | Hold |
| Jan 06, 2023 | Morgan Stanley | Overweight | Overweight | Hold |
| Dec 12, 2022 | Citigroup | - | Neutral | Downgrade |
| Nov 23, 2022 | Credit Suisse | Outperform | Outperform | Hold |
| Aug 01, 2022 | Credit Suisse | Outperform | Outperform | Hold |
Laboratory Corporation of America's last stock rating was published by HSBC on Oct 30, 2024. The company Upgrade its LH rating from "null" to "Buy".
Laboratory Corporation of America Financial Forecast
Laboratory Corporation of America Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $3.03B | $3.06B | $3.03B | $3.78B | $3.67B | $3.61B | $3.70B | $3.90B | $4.06B | $4.06B | $3.84B | $4.16B | $4.49B | $3.90B | $2.77B | $2.82B | $2.95B | $2.93B |
| Avg Forecast | $3.61B | $3.62B | $3.63B | $3.58B | $3.47B | $3.47B | $3.46B | $3.41B | $3.31B | $3.26B | $3.19B | $3.12B | $3.02B | $2.99B | $3.77B | $3.69B | $3.74B | $3.79B | $3.75B | $4.01B | $3.92B | $3.65B | $3.61B | $3.91B | $4.04B | $3.65B | $2.48B | $2.80B | $2.93B | $2.91B |
| High Forecast | $3.65B | $3.66B | $3.67B | $3.62B | $3.51B | $3.51B | $3.50B | $3.46B | $3.33B | $3.26B | $3.19B | $3.12B | $3.03B | $3.02B | $3.81B | $3.73B | $3.78B | $3.79B | $3.75B | $4.01B | $3.92B | $3.65B | $3.61B | $3.91B | $4.04B | $3.65B | $2.48B | $2.80B | $2.93B | $2.91B |
| Low Forecast | $3.57B | $3.58B | $3.59B | $3.54B | $3.43B | $3.43B | $3.42B | $3.37B | $3.30B | $3.26B | $3.19B | $3.12B | $3.01B | $2.93B | $3.72B | $3.65B | $3.70B | $3.79B | $3.75B | $4.01B | $3.92B | $3.65B | $3.61B | $3.91B | $4.04B | $3.65B | $2.48B | $2.80B | $2.93B | $2.91B |
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 10 | 9 | 3 | 4 | 7 | 11 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 5 | 15 | 9 | 9 | 8 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.01% | 1.02% | 0.81% | 1.02% | 0.98% | 0.95% | 0.99% | 0.97% | 1.04% | 1.11% | 1.06% | 1.06% | 1.11% | 1.07% | 1.12% | 1.01% | 1.01% | 1.01% |
Laboratory Corporation of America's average Quarter revenue forecast for Mar 24 based on 4 analysts is $3.12B, with a low forecast of $3.12B, and a high forecast of $3.12B. LH's average Quarter revenue forecast represents a 2.80% increase compared to the company's last Quarter revenue of $3.03B (Dec 23).
Laboratory Corporation of America EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 10 | 9 | 3 | 4 | 7 | 11 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 5 | 15 | 9 | 9 | 8 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $375.70M | $436.70M | $411.70M | $503.00M | $530.30M | $636.00M | $720.40M | $856.50M | $916.50M | $996.00M | $915.40M | $1.25B | $1.47B | $1.15B | $493.60M | $-68.40M | $512.90M | $491.90M |
| Avg Forecast | $667.27M | $669.42M | $671.10M | $661.11M | $641.26M | $640.29M | $639.28M | $630.21M | $611.69M | $602.31M | $588.38M | $998.21M | $557.46M | $552.65M | $695.87M | $907.46M | $859.49M | $760.15M | $753.28M | $824.97M | $786.38M | $731.95M | $724.94M | $1.02B | $810.07M | $733.24M | $497.98M | $-53.67M | $587.55M | $583.77M |
| High Forecast | $674.70M | $676.88M | $678.57M | $668.48M | $648.40M | $647.42M | $646.40M | $639.42M | $615.38M | $602.48M | $588.38M | $1.20B | $559.31M | $557.81M | $703.62M | $1.09B | $1.03B | $760.15M | $753.28M | $989.96M | $786.38M | $731.95M | $724.94M | $1.23B | $810.07M | $733.24M | $497.98M | $-42.93M | $587.55M | $583.77M |
| Low Forecast | $659.74M | $661.87M | $663.52M | $653.65M | $634.03M | $633.06M | $632.07M | $622.84M | $609.84M | $602.14M | $588.38M | $798.57M | $555.60M | $540.81M | $688.02M | $725.97M | $687.59M | $760.15M | $753.28M | $659.97M | $786.38M | $731.95M | $724.94M | $819.38M | $810.07M | $733.24M | $497.98M | $-64.40M | $587.55M | $583.77M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.67% | 0.79% | 0.59% | 0.55% | 0.62% | 0.84% | 0.96% | 1.04% | 1.17% | 1.36% | 1.26% | 1.22% | 1.82% | 1.57% | 0.99% | 1.27% | 0.87% | 0.84% |
4 analysts predict LH's average Quarter EBITDA for Mar 24 to be $998.21M, with a high of $1.20B and a low of $798.57M. This is 165.69% upper than Laboratory Corporation of America's previous annual EBITDA (Dec 23) of $375.70M.
Laboratory Corporation of America Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 10 | 9 | 3 | 4 | 7 | 11 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 5 | 15 | 9 | 9 | 8 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-167.10M | $183.30M | $188.90M | $212.90M | $76.10M | $352.80M | $358.60M | $491.60M | $553.60M | $587.30M | $467.40M | $769.60M | $938.30M | $703.40M | $231.60M | $-317.20M | $227.10M | $220.70M |
| Avg Forecast | $356.87M | $368.16M | $396.53M | $365.68M | $337.01M | $339.40M | $346.68M | $325.67M | $287.59M | $293.08M | $318.69M | $581.90M | $274.90M | $281.32M | $323.73M | $529.00M | $518.60M | $337.98M | $340.27M | $480.91M | $432.05M | $356.08M | $403.58M | $628.73M | $587.30M | $384.39M | $72.81M | $-248.88M | $202.68M | $206.10M |
| High Forecast | $362.03M | $373.49M | $402.27M | $370.98M | $341.89M | $344.31M | $351.70M | $338.17M | $295.16M | $296.10M | $318.69M | $698.29M | $284.09M | $290.64M | $328.41M | $634.81M | $622.32M | $337.98M | $340.27M | $577.10M | $432.05M | $356.08M | $403.58M | $754.48M | $587.30M | $384.39M | $72.81M | $-199.10M | $202.68M | $206.10M |
| Low Forecast | $351.63M | $362.76M | $390.71M | $360.32M | $332.07M | $334.42M | $341.60M | $312.35M | $279.19M | $290.07M | $318.69M | $465.52M | $270.72M | $263.53M | $318.98M | $423.20M | $414.88M | $337.98M | $340.27M | $384.73M | $432.05M | $356.08M | $403.58M | $502.98M | $587.30M | $384.39M | $72.81M | $-298.66M | $202.68M | $206.10M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -0.61% | 0.65% | 0.58% | 0.40% | 0.15% | 1.04% | 1.05% | 1.02% | 1.28% | 1.65% | 1.16% | 1.22% | 1.60% | 1.83% | 3.18% | 1.27% | 1.12% | 1.07% |
Laboratory Corporation of America's average Quarter net income forecast for Dec 23 is $274.90M, with a range of $270.72M to $284.09M. LH's average Quarter net income forecast represents a 49.97% increase compared to the company's last Quarter net income of $183.30M (Sep 23).
Laboratory Corporation of America SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 10 | 9 | 3 | 4 | 7 | 11 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 5 | 15 | 9 | 9 | 8 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $532.90M | $525.50M | $505.80M | $553.60M | $536.50M | $510.00M | $486.00M | $464.10M | $543.70M | $519.90M | $458.70M | $429.80M | $518.00M | $419.50M | $396.30M | $395.50M | $413.90M | $401.50M |
| Avg Forecast | $495.50M | $497.10M | $498.35M | $490.93M | $476.19M | $475.47M | $474.72M | $467.98M | $454.23M | $447.27M | $436.92M | $549.35M | $413.96M | $410.39M | $516.74M | $499.41M | $509.88M | $519.35M | $514.65M | $454.01M | $537.27M | $500.08M | $495.29M | $351.13M | $553.45M | $500.97M | $340.23M | $310.32M | $401.43M | $398.84M |
| High Forecast | $501.02M | $502.64M | $503.90M | $496.40M | $481.49M | $480.76M | $480.01M | $474.82M | $456.97M | $447.39M | $436.92M | $659.22M | $415.33M | $414.22M | $522.50M | $599.29M | $611.86M | $519.35M | $514.65M | $544.81M | $537.27M | $500.08M | $495.29M | $421.35M | $553.45M | $500.97M | $340.23M | $372.38M | $401.43M | $398.84M |
| Low Forecast | $489.91M | $491.49M | $492.72M | $485.39M | $470.82M | $470.10M | $469.36M | $462.51M | $452.86M | $447.14M | $436.92M | $439.48M | $412.58M | $401.60M | $510.91M | $399.53M | $407.90M | $519.35M | $514.65M | $363.21M | $537.27M | $500.08M | $495.29M | $280.90M | $553.45M | $500.97M | $340.23M | $248.25M | $401.43M | $398.84M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.29% | 1.28% | 0.98% | 1.11% | 1.05% | 0.98% | 0.94% | 1.02% | 1.01% | 1.04% | 0.93% | 1.22% | 0.94% | 0.84% | 1.16% | 1.27% | 1.03% | 1.01% |
Laboratory Corporation of America's average Quarter SG&A projection for Mar 24 is $549.35M, based on 4 Wall Street analysts, with a range of $439.48M to $659.22M. The forecast indicates a 3.09% rise compared to LH last annual SG&A of $532.90M (Dec 23).
Laboratory Corporation of America EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 10 | 9 | 3 | 4 | 7 | 11 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 5 | 15 | 9 | 9 | 8 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-1.95 | $2.12 | $2.14 | $2.41 | $0.86 | $3.91 | $3.89 | $5.27 | $5.81 | $6.10 | $4.80 | $7.88 | $9.62 | $7.22 | $2.38 | $-3.27 | $2.34 | $2.26 |
| Avg Forecast | $4.23 | $4.36 | $4.70 | $4.33 | $3.99 | $4.02 | $4.11 | $3.86 | $3.41 | $3.47 | $3.78 | $3.48 | $3.26 | $3.33 | $3.84 | $3.40 | $3.53 | $4.01 | $4.04 | $5.13 | $5.13 | $4.22 | $4.79 | $6.40 | $6.97 | $4.56 | $0.86 | $1.85 | $2.40 | $2.44 |
| High Forecast | $4.29 | $4.43 | $4.77 | $4.40 | $4.05 | $4.08 | $4.17 | $4.01 | $3.50 | $3.51 | $3.78 | $3.48 | $3.37 | $3.44 | $3.89 | $3.45 | $3.58 | $4.01 | $4.04 | $5.13 | $5.13 | $4.22 | $4.79 | $6.40 | $6.97 | $4.56 | $0.86 | $1.85 | $2.40 | $2.44 |
| Low Forecast | $4.17 | $4.30 | $4.63 | $4.27 | $3.93 | $3.96 | $4.05 | $3.70 | $3.31 | $3.44 | $3.78 | $3.48 | $3.21 | $3.12 | $3.78 | $3.35 | $3.47 | $4.01 | $4.04 | $5.13 | $5.13 | $4.22 | $4.79 | $6.40 | $6.97 | $4.56 | $0.86 | $1.85 | $2.40 | $2.44 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -0.60% | 0.64% | 0.56% | 0.71% | 0.24% | 0.98% | 0.96% | 1.03% | 1.13% | 1.44% | 1.00% | 1.23% | 1.38% | 1.58% | 2.76% | -1.77% | 0.97% | 0.92% |
According to 7 Wall Street analysts, Laboratory Corporation of America's projected average Quarter EPS for Dec 23 is $3.26, with a low estimate of $3.21 and a high estimate of $3.37. This represents a 53.63% increase compared to LH previous annual EPS of $2.12 (Sep 23).
Laboratory Corporation of America Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HUM | Humana | $283.14 | $445.86 | 57.47% | Hold |
| LH | Laboratory Corporation of America | $238.18 | $281.25 | 18.08% | Buy |
| DGX | Quest Diagnostics | $156.84 | $166.62 | 6.24% | Buy |
| UHS | Universal Health Services | $201.01 | $208.47 | 3.71% | Hold |
| HOLX | Hologic | $77.54 | $80.21 | 3.44% | Buy |
| WAT | Waters | $376.72 | $356.80 | -5.29% | Buy |